Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Sumitovant_Biopharma
|
| gptkbp:CEO |
gptkb:David_Marek
|
| gptkbp:developedDrug |
gptkb:Myfembree
gptkb:Orgovyx gptkb:Relugolix |
| gptkbp:focusesOn |
prostate cancer
women's health endometriosis uterine fibroids |
| gptkbp:foundedBy |
gptkb:Roivant_Sciences
|
| gptkbp:foundedIn |
2016
|
| gptkbp:headquartersLocation |
gptkb:London,_United_Kingdom
|
| https://www.w3.org/2000/01/rdf-schema#label |
Myovant Sciences
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:parentCompany |
gptkb:Sumitovant_Biopharma
|
| gptkbp:publiclyTraded |
gptkb:NYSE:_MYOV
|
| gptkbp:website |
https://www.myovant.com/
|
| gptkbp:bfsParent |
gptkb:Roivant_Sciences
|
| gptkbp:bfsLayer |
5
|